Dale Hershman "The Sick Economist"’s Post

New, Emerging Treatment Options for Patients With Multiple Myeloma: In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. #finance #pharmacy #lifesciences

Sirius begins patient dosing in phase 1 trial of next─generation, long─acting factor XI siRNA anticoagulant to treat thromboembolic disorders

Metabolic Disorders Solve Programme   We see that metabolic disorders are increasing day by day in the world and many people and organizations are trying to solve them. They make everyday new medicine combinations. In this way, all Allopathic, Ayurveda, Homeopathic, colour path, Iso path, naturopathy, Antipathy, Zyso pathy, Bio-chemic- path, fruit path, vitamin path, home path, acupressure path, acupuncture path, spiritual path, rake path electro-homoeopath, leaf path, flower path, Unani, Siddha, and Every country have Indigenous systems of medicine, Traditional systems of medicine but all are failed to cure diabetes and metabolic disorders All kinds of metabolic disorders first time has no signs and symptoms and no discomfort, but when problems arise in the body we go to the Doctor because they develop very slowly and produce many kinds of diseases. We see that all kinds of metabolic disorders take place due to mutations of enzymes, lipids, and any food we eat which means we are not eating properly as required for digestion and mixing all enzymes. To solve this problem I wrote a Book (English) “Your Health Is In Your Mouth” (Hindi) “Aap Ka Sawasth Aap Ke Muh Me” You can find in a Google search

Congratulations to Daiichi Sankyo on its Enhertu's new key indications approved by FDA! The pioneering new-gen ADC drug by Daiichi Sankyo US was just accelerated approved by FDA for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. Enhertu is now the first and only tumour-agnostic approval of a HER2-directed therapy and ADC by FDA. ADC is one of topics of Chinese Antibody Society's 2024 Annual Conference which will take place in Cambridge, MA, USA, on Saturday, May 11, 2024. You are welcome to register for the conference right NOW via the following link. https://lnkd.in/ecmFPA4v #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #adc #adcs #antibodydrugconjugate # #antibodydrugconjugates #annualmeeting #annualconference

Cardiol Therapeutics Inc. (@cardiolrx) recently announced positive topline results from its Phase II MAvERIC-Pilot study, investigating the impact of CardiolRx™ on patients with symptomatic recurrent pericarditis. The study enrolled 27 adult patients across prominent clinical sites in the U.S., including the Mayo Clinic, Cleveland Clinic, and Massachusetts General Hospital. The results demonstrated a significant reduction in pericarditis pain, with the mean pain score dropping from 5.8 at baseline to 2.1 (64%) after eight weeks of treatment. Additionally, 80% of patients with elevated baseline C-reactive protein (CRP) levels achieved normalization, indicating a substantial reduction in inflammation. 'We are delighted to share the exceptional primary endpoint data from the MAvERIC-Pilot study, which demonstrated that oral administration of our small molecule CardiolRx™ led to marked reductions in pericarditis pain and inflammation,' said David Elsley, President & CEO of Cardiol Therapeutics. With an estimated 38,000 patients in the U.S. experiencing recurrent pericarditis annually, the need for effective treatments is critical. Cardiol Therapeutics aims to provide an accessible and non-immunosuppressive therapeutic option, potentially surpassing existing therapies. The positive results set the stage for a forthcoming Phase III trial. #RecurrentPericarditis #CardiolTherapeutics #CardiolRx #ClinicalTrials #Biotechnology #Healthcare @cardiolrx @mayoclinic @clevelandclinic @massgeneralnews

Recognizing the imprecision of initially establishing a drug dose, the FDA initiated Project Optimus in 2021, the goal of which is to optimize the treatment dose in relation to tolerability. The author and colleagues conducted a clinical trial of the "less is more" approach to drug dosing. Azacitidine (Vidaza) is approved by the FDA to treat myelodysplastic syndromes (MDS) with 7-day dosing on a 28-day chemotherapy cycle. It prolongs survival in patients with higher-risk MDS, but the 7-day dosing schedule is probably too toxic for patients with lower-risk MDS. Decitabine (Dacogen) is also approved to treat MDS, with 5-day dosing on a 28-day chemotherapy cycle. Bottom line: 3 day dosing was just as effective. More such studies are needed for treatments with high real life levels of discontinuation due to intolerability. But where will funding come from? Big Pharma is unlikely to promote research that may negatively affect it’s bottom line. #chemotherapydosing #myelodysplasticsyndrome #mds

In one of the most highly anticipated clinical trial readouts this year, an #RNA silencing treatment developed by Alnylam Pharmaceuticals reduced the risk of death, heart-related hospital visits and hospitalizations by 28% compared to placebo in patients with a heart muscle disease. The results, announced Monday, pave the way for Alnylam’s therapy vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy, a condition in which misfolded proteins build up in the heart and can result in heart failure. If approved, Alnylam could enter a multibillion-dollar market currently dominated by Pfizer. #clinicaltrials #clinicalresults #readout #RNAsilencing #heartmuscledisease #vutrisiran #heartdisease #cardiology #cardio #ATTRcardiomyopathy #patients #PhaseIII #clinicaldata

Latest Healthcare News & Updates: Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Imfinzi and Chemotherapy Combination Gains US Approval for Mismatch Repair Deficient Advanced Endometrial Cancer Nipocalimab Shows Notable Efficacy in Reducing Sjögren’s Disease Symptoms in Recent Phase II Study FDA Grants Approval for Augtyro, an Advanced Tyrosine Kinase Inhibitor (TKI), to Treat Patients with NTRK-Positive Advanced or Metastatic Solid Tumors FDA Approves Farxiga for Treating Type-2 Diabetes in Children Get more detailed analysis, at: https://lnkd.in/g3Dri64i #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

🚀 Exciting News from Kyverna Therapeutics! 🌟 #FDA #FastTrack #InnovationInHealthcare #MultipleSclerosisTherapy #KyvernaTherapeutics 🔬 The FDA has just granted fast track designation to Kyverna Therapeutics' groundbreaking CAR T-cell therapy, KYV-101, specifically aimed at treating multiple sclerosis (MS). This is a major leap forward in autoimmune disease treatment, showcasing Kyverna's commitment to innovative healthcare solutions. 👩🔬KYV-101, an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell therapy, is designed to target the CD19 protein on the B cell surface - a key player in various autoimmune diseases. This therapy represents a novel approach, modifying patients' T cells to effectively identify and eliminate B cells. 🧬 Originating from a collaborative effort with the US National Institutes of Health, the CAR in KYV-101 has been engineered for enhanced tolerability and has already shown promise in a 20-subject Phase I oncology trial. 🔎 Following the FDA's fast track designation for KYV-101 in myasthenia gravis last month, this new status for MS treatment accelerates the development and review process, addressing a critical unmet medical need. 🌍 As a clinical-stage biopharmaceutical leader, Kyverna is not stopping here. Plans are underway for further trials of KYV-101 in systemic sclerosis, myasthenia gravis, and multiple sclerosis, reinforcing their dedication to transforming the treatment landscape for autoimmune diseases. 💡 Kyverna CEO Peter Maag remarks, “This marks another important milestone in our endeavor to change the treatment paradigm with KYV-101.” 🔗 Join us in celebrating this significant advancement in healthcare and stay tuned for more updates on Kyverna’s journey in revolutionizing autoimmune disease treatment! #HealthcareInnovation #CARTherapy #AutoimmuneDisease #ClinicalTrials #Biopharmaceuticals #KyvernaUpdate #HealthTech #MedicalAdvancement

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) unveiled promising results from its #BEXMAB trial at a leading medical conference, showcasing a new drug's effectiveness in treating aggressive #BloodCancers, and offering hope for advanced treatment options. Researchers focused on a new drug, #bexmarilimab, designed to treat aggressive forms of #BloodCancer, specifically #MyelodysplasticSyndromes (MDS). MDS is a group of disorders caused by poorly formed or dysfunctional blood cells, often leading to severe health complications. Remarkably, every patient in the two key groups of the study responded positively to the treatment. These groups included patients with high-risk MDS, a more severe form of the disease, and those for whom previous standard treatments had failed. More at #Proactive #ProactiveInvestors #AIM #OTC #FARN #FPHAF #FaronPharmaceuticals #FaronPharma #Faron http://ow.ly/anPA1055gJJ